Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-16

Clinical Trial Update: Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial [Phase 4]

View source ↗

Summary

Allergan completed the Phase 4 SMART-II trial of Sanctura (trospium chloride) for overactive bladder, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sanctura (trospium chloride)

Snippet

Sponsor: Allergan | Conditions: Overactive Bladder | Phase 4 | Status: COMPLETED | Results posted: 2012-08-16